All In Biotech

Drug Trial Radar · NCT07462143

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

A Randomized, Multicenter, Phase Ⅱ/Ⅲ Study of RC148 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy as First-line Treatment for Unresectable or Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 12, 2026

Primary completion

May 12, 2027

Study completion Dec 31, 2030

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)

Conditions

  • Colorectal (Colon or Rectal) Cancer

Interventions

  • RC148 (Dose 1) plus Capecitabine and OxaliplatinDrug

    RC148 (Dose 1) plus Capecitabine and Oxaliplatin

  • RC148 (Dose 2) plus Capecitabine and OxaliplatinDrug

    RC148 (Dose 2) plus Capecitabine and Oxaliplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: 24 months

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanjing, Guangxi, China · Recruiting

  • The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Tongji Medical College of Huazhong University of Science &Technology

    Wuhan, Hubei, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China · Recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • People's Hospital of Tianjin

    Tianjin, Tianjin Municipality, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.